Impact of Nirogacestat on Pain, a Key Symptom in Patients With Desmoid Tumors: Results From the Phase 3 DeFi Study

Winette T.A. van der Graaf, ¹ Mrinal M. Gounder,² Ravin Ratan, ³ Cristina Ivanescu, ⁴ James Marcus, ⁵ Timothy Bell, ⁶ Allison Lim,⁶ L. Mary Smith, ⁶ Ana B. Oton,⁶ Sandra Goble, ⁷ Thierry Alcindor,⁸ Patrick Schöffski, ⁸ Breelyn A. Wilky,¹⁰ Richard F. Riedel,¹¹ Charlotte Benson,¹² Nam Quoc Bui,¹³ Rashmi Chugh,⁴ Shivaani Kummar,¹⁸ Bernd Kasper¹⁸ Tepartment of Medica Oncology, Netherlands Cancer Institue, American, The Veherlands, Sacona Medical Oncology, Department of Medical Oncology, Division of Cancer Medical Oncology, Department of Medical Oncology, Division of Cancer Medical Oncology, Divisio



INTRODUCTION

- Desmoid tumors (aggressive fibromatosis) are rare, locally invasive, soft-tissue tumors that can result in severe pain, functional impairment, and other complications $^{\rm sd}$
- Pain is the most debilitating symptom reported by patients with desmoid tumors, and the potential for dependency on narcotics is a substantial concern¹⁰
- As many as 60% of patients with desmoid tumors experience chronic pain and pain may indicate desmoid tumor progression⁵⁰
- Pain reduction is a key treatment goal for patients with desmoid tumors¹²⁵⁹
- Nirogacestat is an investigational, oral, small-molecule, selective gammasecretase inhibitor evaluated for the treatment of desmoid tumors in the international phase 3 Desmoid Fibromatosis (DeFi) study (NCT03785964)⁵
- In DeFi, nirogacestat (n=70) significantly improved progression-free survival (the primary endpoint) compared with placebo (n=72) in patients with progressing desmoid tumors (hazard ratio: 0.29 [95% CI, 0.15–0.55]; two-sided *P*<0.001)⁴
- Nirogacestat also achieved a significant and clinically meaningful reduction in pain severity by 1.51 points (on a 10-point scale) compared with placebo at cycle 10 (P<0.001) per the prespecified secondary endpoint of "worst pain" from the Brief Pain Inventory–Short Form (BPI-SF)
- Additional assessment tools, which included pain measurements, were reported by patients in DeFi to further characterize treatment impact on this key symptom

OBJECTIVE

 To evaluate the impact of nirogacestat on desmoid tumor pain (secondary and exploratory study endpoints) in the phase 3 DeFi study

METHODS

- DeFi was a phase 3, global, double-blind, randomized, placebo-controlled study evaluating the efficacy and safety of nirogacestat in patients aged 18 years or older with a histologically confirmed diagnosis of progressing desmoid tumors*
- Patients received oral nirogacestat (150 mg) or placebo twice daily, taken continuously in 28-day cycles until trial completion, disease progression, death, or trial discontinuation due to other reasons⁴
- During the DeFi study, patients completed three assessment tools (including pain measurements) at home using electronic devices; readouts were taken each cycle and assessed at the prespecified cycle 10
- The BPI-SF,¹⁰ which includes assessment of average "worst pain" intensity scored between 0 (no pain) and 10 (pain as bad as you can imagine)
- The GOunder/Desmoid Tumor Research Foundation DEsmoid Symptom Scale (GODDESS-DTSS) pain domain," which includes questions about worst "pain," "dull pain," and "shooting pain," and is scored between 0 (no pain) and 10 (pain as bad as you can imagine)
- The European Organisation for Research and Treatment of Cancer Core Quality of Life Questionnaire (EORTC QLQ-C30) two-item pain subscale," which captures "pain" and "pain interference with daily activities" and is scored between 0 and 100, with higher scores denoting worse pain or more interference
- Change from baseline in pain scores was compared between treatment arms at cycle 10 and overall, using mixed-models repeated measures (MMRM) analyses with visit as a fixed effect, and baseline score and stratification factor (primary tumor location) as fixed-effects covariates. The proportions of

patients with clinically meaningful pain reduction (defined using prespecified thresholds) were compared between treatment arms using a stratified Cochran-Mantel-Haenszel test at cycle 10

> Cycle 10 was prespecified as the post-treatment time point for between-arm comparisons to allow adequate time for a treatment effect to be observed

RESULTS

BASELINE CHARACTERISTICS

- From May 2019 through August 2020, a total of 142 patients were randomized (70 to the nirogacestat group and 72 to the placebo group) across 37 sites in the United States, Canada, and Europe^a
- Baseline patient characteristics (Table 1) were generally similar between groups and representative of the general patient population with desmoid tumors⁴

Table 1. Baseline patient characteristics

CHARACTERISTICS	NIROGACESTAT (n=70)	PLACEBO (n=72)	
Median age (range), years	33.5 (18–73)	34.5 (18–76)	
Sex, n (%)			
Female	45 (64)	47 (65)	
Male	25 (36)	25 (35)	
Target tumor location, n (%)			
Intra-abdominal	17 (24)	18 (25)	
Extra-abdominal	53 (76)	54 (75)	
Focal category, n (%)			
Single	43 (61)	41 (57)	
Multifocal	27 (39)	31 (43)	
Median target tumor size [†] per RECIST (IQR), mm	91.6 (64.7–134.1)	115.7 (73.5–161.7)	
BPI-SF uncontrolled pain, n (%):	27 (39)	31 (43)	
BPI-SF "worst pain" score			
Mean (SD)	3.2 (3.23)	3.3 (3.31)	
GODDESS-DTSS pain score			
Maaa (SD)	2.6 (2.57)	2.0 (2.80)	

- "Sum of the longest damnetes for target tumors. "Uncontrolled part was defined as a BPI-SF average worst pain-intensity score of more than 4 (range, 0 to 10, with higher scores indicating worse pain). Scores were calculated as the average of the daily scores for worst pain during the 7-day period before the baseline visit.
- BPI-SF, Brief Pain Inventory-Short Form; EORTC QLQ-C30, European Organisation for Research and Treatment of Cancer Core Quality of Life Questionnaire; GODDESS-DTSS, Gounden/Desmoid Tumor Research Foundation DEsmoid Symptom Scale; IQR, interquantile ranger, RECIST, Response Evaluation Criteria in Solid Tumors; SD, Standard deviation.

ACKNOWLEDGMENTS: This presentation was supported by SpringWorks Therapeutics, Inc. Writing and editing support was provided by Jeffrey Walter and Daria Renshaw of IQVIA with funding from SpringWorks Therapeutics, Inc.

REFERENCES: 1. Kasper B, et al. Ann Oncol. 2017;28:2399–2408. 2. Penel N, et al. Curr Opin Oncol. 2017;29:268–274. 3. Husson O, et al. Support Care Cancer. 2019;27:965–980. 4. Gounder MM, et al. Cancer. 2020;126:531–539. 6. Ourom O P, et al. BMC Cancer. 2021;21:437. 6. Riedel RF, et al. Cancer. 2022;128:3027–3040. 7. Schut AW, et al. Cancers (Basel). 2022;14:708. 8. Gounder M, et al. N Engl J Med. 2023;388:898–912. 9. Penel N, et al. Inf J Cancer. 2023;153:407–416. 10. Brief Pain Inventory (Short Form). Available at: http://www.npcrc. org/lies/news/briefpain_short.pdf 11. EORTC Quality of Life of Cancer Patients. Available at: https://qoi.eortc.org/questionnaire/eortc-qiq-c30/ 12. Farrar JT, et al. Pain. 2000;8:287–294. 13. Dworkin RH, et al. J Pain. 2008;9:105–121.

Figure 1. Change from baseline in BPI-SF "worst pain" intensity score




Figure 2. Change from baseline in GODDESS-DTSS pain score



Figure 3. Change from baseline in EORTC QLQ-C30 pain subscale



C, cycle; Cl, confidence interval; LS mean, least-squares mean; SE, standard error.

PAIN ASSESSMENTS

 Statistically significant and clinically meaningful pain reduction was observed with nirogacestat compared with placebo at cycle 10 across all three assessment tools evaluated in DeFi; exploratory analyses show that those receiving nirogacestat quickly improved, with separation between treatment arms observed as early as cycle 2 and sustained throughout treatment

BPI-SF

 At cycle 10, nirogacestat significantly reduced pain sevently per the BPI-SF "worst pain" score (0–10 range) by 1.55 points (SE=0.26) compared with 0.05 points (SE=0.27) with placebo (one-sided P<0.001) (Figure 1)

GODDESS-DTSS

 At cycle 10, nirogacestat significantly reduced mean baseline pain per the GODDESS-DTSS pain score (0–10 range) by 1.78 points (SE=0.27) compared with an increase in pain by 0.34 points (SE=0.28) with placebo (one-sided P<0.001) (Figure 2)

EORTC QLQ-C30

 At cycle 10, nirogacestat significantly reduced mean baseline pain per the EORTC QLQ-C30 pain subscale (0–100 range) by 22.36 points (SE=3.39) compared with an increase in pain by 7.00 points (SE=3.65) with placebo (one-sided P<0.001) (Figure 3)

CLINICALLY MEANINGFUL PAIN REDUCTION FROM BASELINE (RESPONDER ANALYSIS)

- Per the BPI-SF "worst pain" score (0–10 range), a statistically significant greater proportion of patients achieved a clinically meaningful within-patient pain reduction from baseline (of ≥2.0 points) with nirogacestat (68.2%) than with placebo (26.3%) at cycle 10 (one-sided P=0.001) (Table 2)
- Per the GODDESS-DTSS pain score (0–10 range), a statistically significant greater proportion of patients achieved a clinically meaningful within-patient pain reduction (of ≥1.9 points) with nirogacestat (58.7%) than with placebo (18.9%) at cycle 10 (one-sided P-0.001) (Table 2)

Table 2. Proportion of patients with clinically meaningful pain reduction from baseline at cycle 10

		Responder (%)*		Odds ratio		
Measure	Response threshold [†]	Nirogacestat (n=70)	Placebo (n=72)	Value	95% CI	P (one-sided)
BPI-SF "worst pain" score	2.0 points	68.2	26.3	6.08	1.95–18.98	0.001
GODDESS- DTSS pain score	1.9 points	58.7	18.9	6.24	2.16-17.99	<0.001

Note: analysis is based on a multiple imputation model and the denominator is ITT population.

"For the BPLSF" worst pain "responder analysis, the value of 2 points was used as the threshold to determine clinically meaningful improvement. Threshold values of 30% or greater change, or 2 point of greater change, or numerical training dBPLSF score, have bee proposed in the literature to detect clinically important improvements in cancer-related breakthrough pain and chronic pain states¹¹¹. Within-patient clinically meaningful response threshold.

BPI-SF, Brief Pain Inventory-Short Form; CI, confidence interval; GODDESS-DTSS, GOunder/Desmoid Turnor Research Foundat DEsmoid Symptom Scale; ITT, intent-to-treat.

CONCLUSIONS

- In the phase 3 DEFi study, patients with progressing desmoid tumors who received nirogacestat achieved a rapid, sustained, and consistent reduction in different aspects of pain (e.g. worst pain, dull pain, shooting pain, pain interference with daily activities) compared with those who received placebo
- Significantly greater proportions of patients achieved clinically meaningful reduction in pain with nirogacestat compared with placebo
- The benefit of nirogacestat versus placebo in reducing pain was consistent across multiple patient-completed assessment tools, which included pain measurements
- As pain is the most commonly reported symptom by patients with desmoid tumors, pain reduction should be a key clinical study endpoint and treatment goal

Originally presented at the American Society for Clinical Oncology (ASCO) Annual Meeting 2023. Encore presentation at the National Community Oncology Dispensing Association (NCODA) International Fall Summit • October 25–27, 2023 • Orlando, FL, USA